What is the difference between HGH Fragment 176-191 and AOD-9604?

HGH Fragment 176-191 is the unmodified C-terminal peptide sequence of human growth hormone (amino acids 176–191). AOD-9604 is HGH Fragment 176-191 with a tyrosine added to the N-terminus for greater stability and longer half-life. Both target the same lipolytic mechanism via beta-3 adrenergic receptor activation in adipose tissue; AOD-9604 has the more formal research history including Phase II/IIb clinical trials and FDA GRAS status. HGH Frag 176-191 is the precursor compound with more community use history and lower cost.

Why is fasted cardio important with HGH Fragment 176-191?

The lipolytic mechanism of HGH Fragment 176-191 (HSL activation → free fatty acid release) is most active in the fasted state when insulin is low. Exercise increases fat oxidation simultaneously. The combination — fragment activates fat breakdown, exercise burns the released free fatty acids — is mechanistically synergistic. Without exercise, free fatty acids released by lipolysis may be re-esterified back into fat rather than oxidized. Fasted morning dosing with 20–30 minutes of cardio is the community's most consistently effective protocol.

COMPOUND LIBRARY·HGH FRAGMENT 176-191

COMPOUND PROFILE · PEPPERLEDGER

HGH Fragment 176-191 (HGH Frag)

Type

Synthetic peptide fragment of human growth hormone — the C-terminal region (amino acids 176–191) responsible for GH's lipolytic activity

Class

Lipolytic GH fragment — activates fat cell breakdown via the GH receptor's lipolytic domain without anabolic or IGF-1 effects

Administration

Subcutaneous injection · Intranasal (less bioavailable)

Half-life

~30 minutes

Most studied use

Targeted fat loss without GH's growth, IGF-1, or glucose effects

Regulatory status

Not FDA-approved · Research chemical · Precursor to AOD-9604 which received FDA GRAS status as a food ingredient

Human evidence

Limited — most human evidence is for AOD-9604 (the modified version). HGH Frag 176-191 itself has minimal human trial data.

Preclinical evidence

Strong — fat-specific lipolytic mechanism confirmed across multiple models

EDUCATIONAL TOOL — NOT MEDICAL ADVICE

What is HGH Fragment 176-191?

HGH Fragment 176-191 is the C-terminal peptide sequence of human growth hormone that is responsible for GH's lipolytic (fat-burning) effects. The full GH molecule has multiple structural domains: some drive anabolic effects via IGF-1 (bone and muscle growth, glucose effects), while others drive lipolytic effects in adipose tissue. The fragment 176-191 isolates the lipolytic domain — the portion that activates fat breakdown without triggering the growth-promoting mechanisms.

The pharmacological concept is the same as AOD-9604: separate the fat-burning effects of GH from its growth-promoting effects. AOD-9604 is HGH Fragment 176-191 with a tyrosine added to the N-terminus for stability — making it slightly more potent and longer-lasting. Both target the same mechanism; AOD-9604 has the more formal research history including Phase II/IIb trials and FDA GRAS status. HGH Frag 176-191 is the precursor compound that's been in biohacker use longer and at lower cost.

The honest expectation: HGH Fragment 176-191 is a targeted metabolic tool for visceral and stubborn fat, not a primary weight loss compound. Users should not expect GLP-1 class weight loss. The compound's appeal is specificity — addressing fat metabolism directly in fat cells, without systemic metabolic complexity. Like AOD-9604, it does not elevate IGF-1, does not cause insulin resistance, and does not promote bone or soft tissue growth.

How it works

GH Lipolytic Domain — Isolated Function

Human growth hormone activates two functionally distinct downstream pathways: anabolic (via IGF-1 production and direct tissue growth) and lipolytic (via direct activation of hormone-sensitive lipase in adipose tissue). These pathways are mediated by different structural regions of the GH molecule. Fragment 176-191 contains the primary lipolytic domain — it activates fat cell breakdown without engaging the receptor interactions that drive IGF-1 production or anabolic signaling.

Beta-3 Adrenergic Receptor Activation

The primary lipolytic mechanism of HGH Fragment 176-191 involves activation of beta-3 adrenergic receptors in adipose tissue. Beta-3 AR activation stimulates hormone-sensitive lipase (HSL), which hydrolyzes stored triglycerides into free fatty acids and glycerol — the direct lipolytic event. This mechanism is well-characterized in rodent adipose tissue; the human translation depends on beta-3 AR expression in human fat, which is lower than in rodents.

No IGF-1, No Glucose Effects — The Clean Profile

HGH Fragment 176-191 does not significantly elevate IGF-1 levels, does not cause insulin resistance, and does not drive bone or soft tissue growth. These exclusions are mechanistically confirmed: the fragment lacks the structural regions that interact with GH-binding protein and the sites that drive IGF-1 axis signaling. For users specifically avoiding IGF-1-related risks or glucose effects, this clean metabolic profile is the primary appeal.

What the research shows

EVIDENCE NOTE — MOST HUMAN DATA IS FOR AOD-9604

Most human evidence in this mechanistic space comes from AOD-9604 trials (see AOD-9604 page). HGH Fragment 176-191 itself has limited published human data — the compound was largely superseded in formal research by the modified AOD-9604. The preclinical evidence for the mechanism is shared between both.

STUDYJournal of Molecular Endocrinology · 1990

HGH fragment 176-191 stimulates lipolysis in isolated fat cells

Ng FM et al.

Original characterization of GH fragment 176-191 lipolytic activity in rat adipocytes. Established that this region of GH drives fat breakdown independently of IGF-1 signaling. Foundation for both HGH Frag 176-191 and AOD-9604 development.

View on PubMed →

STUDYEndocrinology · 1999

Metabolic effects of HGH fragments: lipolysis without growth promotion

Heffernan M et al.

Comparative study of GH fragment effects on fat vs. growth in animal models. HGH Frag 176-191 produced fat reduction without bone growth or IGF-1 elevation. Preclinical basis for the fat-specific mechanism.

View on PubMed →

WHAT THE RESEARCH SHOWS

✓KNOWN

✓Lipolytic mechanism in fat cells — beta-3 AR and HSL activation (preclinical confirmed)
✓No IGF-1 elevation or glucose effects — mechanistically confirmed
✓Fat-specific mechanism separable from GH's anabolic effects
✓Short plasma half-life (~30 min) — frequent dosing needed

?UNCERTAIN

?Human fat loss efficacy at injectable doses (no RCTs for HGH Frag 176-191 itself)
?Optimal dose and frequency for humans
?Whether human beta-3 AR expression is sufficient for meaningful response
?Comparative advantage over AOD-9604 (the more stable modified version)

What the community reports

—Gradual fat reduction — primarily visceral and stubborn fat; described as subtle rather than dramatic over 8–12 week protocols

—Most effective with fasted cardio — users who combine with fasted morning exercise consistently report better results; consistent with the lipolytic mechanism being enhanced in the fasted state

—No appetite suppression — distinct from GLP-1 class; caloric discipline remains fully on the user

—Clean side-effect profile — very few adverse effects reported; some injection site reactions

—AOD-9604 comparison: users who have tried both generally report similar effects; AOD-9604 is slightly more expensive; HGH Frag is the budget version

—Stacked with GH secretagogues: some users run HGH Frag alongside CJC-1295 + ipamorelin for both GH elevation and direct lipolytic effects simultaneously

Common misconceptions

"HGH Fragment 176-191 is the same as AOD-9604."

REALITY

Close but not identical. AOD-9604 is HGH Frag 176-191 with a tyrosine added to the N-terminus, providing greater stability and longer half-life. AOD-9604 has the formal clinical trial history (Phase II/IIb, FDA GRAS status). HGH Frag 176-191 is the unmodified fragment with more community use history but less formal research. Same mechanism, different molecules.

"HGH Fragment burns fat dramatically."

REALITY

The mechanism is real; the human effect size appears modest based on AOD-9604's Phase II/III data. Injectable HGH Frag may perform differently than oral doses tested in trials. Community experience suggests modest, consistent fat reduction over weeks — not dramatic transformation. This is not GLP-1 class efficacy.

"This is a safer alternative to GH therapy."

REALITY

HGH Fragment 176-191 is not GH therapy — it targets only the lipolytic function of GH and does not produce GH's other benefits (IGF-1 elevation, anabolic effects, GH-specific metabolic improvements). It's a targeted fat-loss tool, not a safer form of GH replacement.

LIPOLYTIC PEPTIDE COMPARISON

HGH Frag 176-191: unmodified GH fragment, most community use history, lower cost. AOD-9604: modified version (+ tyrosine), more stable, formal clinical trial history, FDA GRAS status. Tesamorelin: FDA-approved GHRH analogue — visceral fat reduction via full GH axis. Semaglutide: GLP-1 class — dramatically more potent weight loss with established human safety.

RECONSTITUTION CALCULATOR

Peptide in vial (mg)BAC water (mL)Desired dose (mcg)

EDUCATIONAL TOOL — NOT MEDICAL ADVICE · VERIFY WITH YOUR CLINICIAN

AI COACH PREVIEW

I want to run HGH Fragment 176-191 for fat loss. Should I use it instead of AOD-9604?

Good question — let me clarify the actual difference before you decide. HGH Fragment 176-191 and AOD-9604 are not the same compound, even though most people treat them interchangeably. HGH Frag 176-191 is the unmodified C-terminal GH fragment (amino acids 176–191). AOD-9604 is HGH Frag with a tyrosine added to the N-terminus — slightly more stable, longer half-life, and has the formal research history including Phase II/IIb clinical trials and FDA GRAS status as a food ingredient. Same mechanism, different molecules. If I had to pick between them: AOD-9604 has the formal evidence base. HGH Frag 176-191 has been in community use longer and is typically cheaper. If you're running either as a fat-loss tool, the protocol matters more than which one you choose. Key considerations: Fasted morning dosing is the most important variable — lipolysis is highest in the fasted state. Adding 20–30 minutes of cardio after dosing converts freed fatty acids into oxidized fuel rather than letting them be re-esterified. Neither compound suppresses appetite, so caloric discipline is entirely on you — this is not GLP-1 class. What's your primary fat loss goal — general visceral reduction, stubborn area targeting, or trying to avoid appetite suppression from other compounds?

CONTINUE IN THE APP

Open PepperLedger to track your HGH Fragment protocol →

Free to join. No credit card. Ask the Coach about your lipolytic peptide stack once you're in.

Free to join · No credit card · 23-day Pro trial included